Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain
Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin
Executive Summary
The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.